Current management of uveal melanoma

Expert Review of Ophthalmology

Volumn 2, Issue 6, 2007, Pages 939-946

  Ramaiya, Kamalesh J ^a   Harbour, j William ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

charged particle radiotherapy; choroidal melanoma; endoresection; molecular prognostic testing; peptide therapy; plaque radiotherapy; stereotactic radiotherapy; transpupillary thermotherapy; uveal melanoma

Indexed keywords

EID: 84978501205     PISSN: 17469899     EISSN: 17469902     Source Type: Journal    
DOI: 10.1586/17469899.2.6.939     Document Type: Article

References (59)

1. Egan KM, Seddon JM, Glynn RJ, Gragoudas ES, Albert DM. Epidemiologic aspects of uveal melanoma. Surv. Ophthalmol. 32 (4), 239–251 (1988).
2. Singh AD, Bergman L, Seregard S. Uveal melanoma: epidemiologic aspects. Ophthalmol. Clin. North Am. 18 (1), 75–84 (2005).
3. Canning CR, Hungerford J. Familial uveal melanoma. Br. J. Ophthalmol. 72 (4), 241–243 (1988).
4. Young LH, Egan KM, Walsh SM, Gragoudas ES. Familial uveal melanoma. Am. J. Ophthalmol. 117 (4), 516–520 (1994).
5. Kath R, Hayungs J, Bornfeld N et al. Prognosis and treatment of disseminated uveal melanoma. Cancer 72 (7), 2219–2223 (1993).
6. Kujala E, Makitie T, Kivela T. Very long-term prognosis of patients with malignant uveal melanoma. Invest. Ophthalmol. Vis. Sci. 44 (11), 4651–4659 (2003).
7. Seregard S. Long-term survival after ruthenium plaque radiotherapy for uveal melanoma. A meta-analysis of studies including 1,066 patients. Acta. Ophthalmol. Scand. 77 (4), 414–417 (1999).
8. Diener-West M, Earle JD, Fine SL et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18. Arch. Ophthalmol. 119 (7), 969–982 (2001).
9. Bechrakis NE, Bornfeld N, Zoller I, Foerster MH. Iodine 125 plaque brachytherapy versus transscleral tumor resection in the treatment of large uveal melanomas. Ophthalmology 109 (10), 1855–1861 (2002).
10. Puusaari I, Damato B, Kivela T. Transscleral local resection versus iodine brachytherapy for uveal melanomas that are large because of tumour height. Graefes Arch. Clin. Exp. Ophthalmol. 245 (4), 522–533 (2006).
11. Harbour JW, Meredith TA, Thompson PA, Gordon ME. Transpupillary thermotherapy versus plaque radiotherapy for suspected choroidal melanomas. Ophthalmology 110 (11), 2207–2215 (2003).
12. Harbour JW, Murray TG, Byrne SF et al. Intraoperative echographic localization of iodine 125 episcleral radioactive plaques for posterior uveal melanoma. Retina 16 (2), 129–134 (1996).
13. Oosterhuis JA, Journee-de Korver HG, Keunen JE. Transpupillary thermotherapy: results in 50 patients with choroidal melanoma. Arch. Ophthalmol. 116 (2), 157–162 (1998).
14. Harbour JW, Ahmad S, El-Bash M. Rate of resolution of exudative retinal detachment after plaque radiotherapy for uveal melanoma. Arch. Ophthalmol. 120 (11), 1463–1469. (2002).
15. Mills MD, Harbour JW. Lipid exudation following plaque radiotherapy for posterior uveal melanoma. Am. J. Ophthalmol. 141 (3), 594–595 (2006).
16. Finger PT. Tumour location affects the incidence of cataract and retinopathy after ophthalmic plaque radiation therapy. Br. J. Ophthalmol. 84 (9), 1068–1070 (2000).
17. Shields CL, Naseripour M, Cater J et al. Plaque radiotherapy for large posterior uveal melanomas (> or = 8-mm thick) in 354 consecutive patients. Ophthalmology 109 (10), 1838–1849 (2002).
18. Lommatzsch PK, Werschnik C, Schuster E. Long-term follow-up of RuH106/Rh-106 brachytherapy for posterior uveal melanoma. Graefes Arch. Clin. Exp. Ophthalmol. 238 (2), 129–137 (2000).
19. Jampol LM, Moy CS, Murray TG et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19. Ophthalmology 109 (12), 2197–2206. (2002).
20. Tabandeh H, Chaudhry NA, Murray TG et al. Intraoperative echographic localization of iodine-125 episcleral plaque for brachytherapy of choroidal melanoma. Am. J. Ophthalmol. 129 (2), 199–204 (2000).
21. Almony A, Breit S, Zhao H et al. Tilting of radioactive plaques after initial accurate placement for treatment of uveal melanoma. Arch. Ophthalmol. (2007) (In press).
22. Char DH, Kroll SM, Castro J. Long-term follow-up after uveal melanoma charged particle therapy. Trans. Am. Ophthalmol. Soc. 95, 171–187; discussion 187–191 (1997).
23. Char DH, Quivey JM, Castro JR, Kroll S, Phillips T. Helium ions versus iodine 125 brachytherapy in the management of uveal melanoma. A prospective, randomized, dynamically balanced trial. Ophthalmology 100 (10), 1547–1554 (1993).
24. Daftari IK, Char DH, Verhey LJ et al. Anterior segment sparing to reduce charged particle radiotherapy complications in uveal melanoma. Int. J. Radiat. Oncol. Biol. Phys. 39 (5), 997–1010 (1997).
25. Oosterhuis JA, Journee-de Korver HG, Kakebeeke-Kemme HM, Bleeker JC. Transpupillary thermotherapy in choroidal melanomas. Arch. Ophthalmol. 113 (3), 315–321 (1995).
26. Robertson DM, Buettner H, Bennett SR. Transpupillary thermotherapy as primary treatment for small choroidal melanomas. Arch. Ophthalmol. 117 (11), 1512–1519 (1999).
27. Godfrey DG, Waldron RG, Capone A Jr. Transpupillary thermotherapy for small choroidal melanoma. Am. J. Ophthalmol. 128 (1), 88–93 (1999).
28. Shields CL, Shields JA, De Potter P, Kheterpal S. Transpupillary thermotherapy in the management of choroidal melanoma. Ophthalmology 103, 1642–1650 (1996).
29. Dieckmann K, Georg D, Zehetmayer M et al. LINAC based stereotactic radiotherapy of uveal melanoma: 4 years clinical experience. Radiother. Oncol. 67 (2), 199–206 (2003).
30. Mueller AJ, Talies S, Schaller UC et al. Stereotactic radiosurgery of large uveal melanomas with the gamma-knife. Ophthalmology 107 (7), 1381–1387 (2000).
31. Kertes PJ, Johnson JC, Peyman GA. Internal resection of posterior uveal melanomas. Br. J. Ophthalmol. 82 (10), 1147–1153 (1998).
32. Char DH, Miller T, Crawford JB. Eye-wall resection. Trans. Am. Ophthalmol. Soc. 98 (1–2), 153–159 (2000).
33. Damato B, Wong D, Green FD, Mackenzie JM. Intrascleral recurrence of uveal melanoma after transretinal “endoresection”. Br. J. Ophthalmol. 85 (1), 114–115 (2001).
34. Zimmerman LE, McLean IW, Foster WD. Does enucleation of the eye containing a malignant melanoma prevent or accelerate the dissemination of tumour cells. Br. J. Ophthalmol. 62 (6), 420–425 (1978).
35. Singh AD, Rennie IG, Kivela T, Seregard S, Grossniklaus H. The Zimmerman–McLean–Foster hypothesis: 25 years later. Br. J. Ophthalmol. 88 (7), 962–967 (2004).
36. Harbour JW, Murray TG. Management of intraocular tumors. In: Ophthalmic Surgery: Principles and Techniques. Albert D (Ed.). Blackwell Co., MA, USA 682–705 (1998).
37. Woll E, Bedikian A, Legha SS. Uveal melanoma: natural history and treatment options for metastatic disease. Melanoma Res. 9 (6), 575–581 (1999).
38. Gragoudas ES, Egan KM, Seddon JM et al. Survival of patients with metastases from uveal melanoma. Ophthalmology 98 (3), 383–389 (1991).
39. Bedikian AY, Legha SS, Mavligit G et al. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer 76 (9), 1665–1670 (1995).
40. Singh AD, Topham A. Survival rates with uveal melanoma in the United States: 1973–1997. Ophthalmology 110 (5), 962–965 (2003).
41. Eskelin S, Pyrhonen S, Summanen P, Hahka-Kemppinen M, Kivela T. Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment. Ophthalmology 107 (8), 1443–1449 (2000).
42. Onken MD, Ehlers JP, Worley LA et al. Functional gene expression analysis uncovers phenotypic switch in aggressive uveal melanomas. Cancer Res. 66 (9), 4602–4609 (2006).
43. Onken MD, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res. 64, 7205–7209 (2004).
44. Onken MD, Worley LA, Person E et al. Loss of heterozygosity of chromosome 3 detected with single nucleotide polymorphisms is superior to monosomy 3 for predicting metastasis in uveal melanoma. Clin. Cancer Res. 13 (10), 2923–2927 (2007).
45. Worley LA, Onken MD, Person E et al. Transcriptomic versus chromosomal prognostic markers and clinical outcome in uveal melanoma. Clin. Cancer Res. 13 (5), 1466–1471 (2007).
46. Onken MD, Worley LA, Davila RM, Char DH, Harbour JW. Prognostic testing in uveal melanoma by transcriptomic profiling of fine needle biopsy specimens. J. Mol. Diagn. 8 (5), 567–573 (2006).
47. Ehlers JP, Harbour JW. Molecular pathobiology of uveal melanoma. Int. Ophthalmol. Clin. 46 (1), 167–180 (2006).
48. Brantley MA Jr, Harbour JW. Deregulation of the Rb and p53 pathways in uveal melanoma. Am. J. Pathol. 157 (6), 1795–1801 (2000).
49. Harbour JW. Eye cancer: unique insights into oncogenesis: The Cogan Lecture. Invest. Ophthalmol. Vis. Sci. 47 (5), 1736–1745 (2006).
50. Brantley MA Jr, Harbour JW. Inactivation of retinoblastoma protein in uveal melanoma by phosphorylation of sites in the COOH-terminal region. Cancer Res. 60 (16), 4320–4323 (2000).
51. Harbour JW, Worley L, Ma D, Cohen M. Transducible peptide therapy for uveal melanoma and retinoblastoma. Arch. Ophthalmol. 120 (10), 1341–1346 (2002).
52. Mooy CM, Van der Helm MJ, Van der Kwast TH et al. No N-ras mutations in human uveal melanoma: the role of ultraviolet light revisited. Br. J. Cancer 64 (2), 411–413 (1991).
53. Soparker CN, O’Brien JM, Albert DM. Investigation of the role of the ras protooncogene point mutation in human uveal melanomas. Invest. Ophthalmol. Vis. Sci. 34 (7), 2203–2209 (1993).
54. Cruz F 3rd, Rubin BP, Wilson D et al. Absence of BRAF and NRAS Mutations in Uveal Melanoma. Cancer Res. 63 (18), 5761–5766 (2003).
55. Zuidervaart W, van Nieuwpoort F, Stark M et al. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. Br. J. Cancer 92 (11), 2032–2038 (2005).
56. Lefevre G, Glotin AL, Calipel A et al. Roles of stem cell factor/c-Kit and effects of Glivec/STI571 in human uveal melanoma cell tumorigenesis. J. Biol. Chem. 279 (30), 31769–31779 (2004).
57. All-Ericsson C, Girnita L, Muller-Brunotte A et al. c-Kit-dependent growth of uveal melanoma cells: a potential therapeutic target? Roles of stem cell factor/c-Kit and effects of Glivec/STI571 in human uveal melanoma cell tumorigenesis. Invest. Ophthalmol. Vis. Sci. 45 (7), 2075–2082 (2004).
58. Girnita A, All-Ericsson C, Economou MA et al. The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells. Clin. Cancer Res. 12 (4), 1383–1391 (2006).
59. Calipel A, Mouriaux F, Glotin AL et al. Extracellular signal-regulated kinase-dependent proliferation is mediated through the protein kinase A/B-Raf pathway in human uveal melanoma cells. J. Biol. Chem. 281 (14), 9238–9250 (2006).